Castle Creek Arbitrage’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Castle Creek Arbitrage’s Portfolio BIOTW Stock Details BIOTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-50,000	Closed	-$3.11K	–	583
2022 Q4	$3.11K	Hold	50,000	–	–	﹤0.01%	463
2022 Q3	$3K	Hold	50,000	–	–	﹤0.01%	642
2022 Q2	$3K	Hold	50,000	–	–	﹤0.01%	656
2022 Q1	$12K	Hold	50,000	–	–	﹤0.01%	645
2021 Q4	$31K	Hold	50,000	–	–	﹤0.01%	639
2021 Q3	$32K	Hold	50,000	–	–	﹤0.01%	601
2021 Q2	$43K	Hold	50,000	–	–	﹤0.01%	614
2021 Q1	$29K	Buy	+50,000	New	+$35.3K	﹤0.01%	536

Castle Creek Arbitrage's BIOTW Position: Q1 2023 in Review

Castle Creek Arbitrage sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2023, closing a stake of 50,000 shares — an estimated $3.11K sold.

Castle Creek Arbitrage first reported a position in BIOTW in Q1 2021 and held it in 8 quarters. The position peaked at $43K in Q2 2021. 0 funds tracked by Wall St. Rank hold BIOTW as of Q1 2023.

Castle Creek Arbitrage reported no remaining Biotech Acquisition Company Warrant position as of Q1 2023 after selling out during the quarter.
Castle Creek Arbitrage sold 50,000 Biotech Acquisition Company Warrant shares in Q1 2023, an estimated $3.11K.
Castle Creek Arbitrage first reported a position in Biotech Acquisition Company Warrant in Q1 2021 and held it in 8 quarters.
Castle Creek Arbitrage's Biotech Acquisition Company Warrant position peaked at $43K in Q2 2021.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2023.

Based on Castle Creek Arbitrage's 13F filing for Q1 2023, filed 15 May 2023.